3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next? The Apogee setup is the template buyers are chasing: late-stage clinical data, a meaningful addressable market, a strategic fit in immunology, obesity, or oncology, and a market cap that leaves room for a premium.

Using that framework, three Nasdaq-listed names keep surfacing on Wall Street’s M&A watchlists. None has announced a deal. All three carry catalysts inside the next 12 months that could either invite a bid or remove the discount. Here is the countdown, from least likely to most likely to be acquired.

3. Nektar Therapeutics

Nektar Therapeutics (NASDAQ: NKTR) carries the strongest immunology storyline of the group, but the setup is the least urgent. Rezpegaldesleukin, a first-in-class Treg stimulator, hit its primary endpoint in moderate-to-severe atopic dermatitis and is heading into Phase 3 ZENITH-AD initiation by July 2026, with an FDA End-of-Phase 2 meeting for alopecia areata also lined up. That is exactly the Apogee-style profile AbbVie just paid for.

The problem for a would-be acquirer is the entry price. Nektar is up 672.0% over the past year and 55.4% year to date, with a market cap near $2.22 billion. Management raised roughly $460 million in February and another $351 million in April, leaving over $1 billion in cash. Q1 EPS came in at −$1.82, missing the −$1.48 consensus by 22.97%, with revenue of $10.86 million. Freshly funded and pre-Phase 3, Nektar has the resources to remain independent.

2. Viking Therapeutics

Viking Therapeutics (NASDAQ: VKTX) is the most-rumored M&A name in biotech. VK2735 is a GLP-1/GIP dual agonist in both subcutaneous and oral formulations, sitting in the hottest therapeutic category for big pharma. The oral asset showed up to 12.2% mean body weight reduction after 13 weeks in Phase 2, and Phase 3 VANQUISH-1 is fully enrolled with over 4,500 patients ahead of schedule.

So why didn’t it top this list? Because of its size and cash. Viking carries a market cap near $3.76 billion, the largest of the trio, and held approximately $706 million in cash at year-end 2025. Polymarket traders are pricing a 36% probability of an acquisition before 2027, the second-highest odds on the platform’s M&A board. Q4 EPS missed at −$1.38 versus −$0.90, but the market has shrugged off losses. High appeal, lower urgency. Viking can command a steep premium on its own timeline.

1. Syndax Pharmaceuticals

Syndax Pharmaceuticals (NASDAQ: SNDX) has the cleanest takeover setup: the smallest market cap of the three at roughly $1.71 billion, commercial-stage with two FDA-approved drugs, and a built-in strategic acquirer already on the cap table.

Revuforj, a menin inhibitor for relapsed/refractory AML, generated $48.92 million in Q1 2026 net revenue, up 144% year over year. Niktimvo, the CSF-1R antibody for chronic GVHD, is co-commercialized with Incyte and captured ~32% share of the 3L+ chronic GVHD market within its first year. Total Q1 revenue hit $64.86 million, up 223.6% year over year, with EPS of −$0.48 beating the −$0.59 estimate by 18.75%.

Shares are down 8.0% year to date and trade well below their $39 analyst target price, against a 52-week range of $8.59 to $25.59. Analyst coverage skews positive. Cash sits at $352 million, down from $394 million a quarter earlier, and 2026 opex is guided to roughly $400 million. That burn against a depressed share price makes a strategic acquirer the cheapest path forward, and Incyte’s existing Niktimvo partnership economics make it the most logical buyer.

The Bottom Line

The Apogee deal proved that big pharma will pay up for late-stage immunology, and that read-through extends to obesity and oncology assets that match the criteria. Nektar has the science but not the urgency. Viking has the asset everyone wants but the leverage to wait. Syndax has the smallest cap, two launched drugs, real revenue traction, and a partner who already knows the franchise. If the Apogee playbook repeats, Syndax is the one to watch first.